Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.
P2X receptors
adenosine 5′-triphosphate
diabetes
drugs
obesity
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
08
08
2024
revised:
21
09
2024
accepted:
26
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
The role of P2X ionotropic receptors in the behavior of purinergic signaling on pathophysiological processes has been widely studied. In recent years, the important participation of P2X receptors in physiological and pathological processes, such as energy metabolism, characteristic inflammatory responses of the immune system, and nociceptive activity in response to pain stimuli, has been noted. Here, we explore the molecular characteristics of the P2X receptors and the use of the different agonist and antagonist agents recently described, focusing on their potential as new therapeutic targets in the treatment of diseases with emphasis on obesity, diabetes, and some of the complications derived from these pathologies.
Identifiants
pubmed: 39458933
pii: ph17101291
doi: 10.3390/ph17101291
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng